Important note: Information in this article was accurate in August 2004. The state of the art August have changed since the publication date.
 |
AIDSWEEKLY Plus; Monday, August 2, 2004
Staff Medical Writers
According to a study from Germany, "Hodgkin disease (HD) is the most common nonacquired immunodeficiency syndrome (AIDS)-defining malignancy in human immunodeficiency virus (HIV)-infected patients.
"We analyzed the outcome of patients with HIV-associated HD (HIV-HD) with respect to the use and efficacy of highly active antiretroviral therapy (HAART) and other prognostic factors. To evaluate the effects of several variables on overall survival (OS), Kaplan-Meier statistics and extended Cox regression analysis were performed."
"Response to HAART was used as a time-dependent variable and was defined as an increase of >0.1x109 CD4 cells/L or at least one viral load <500 copies/mL during the first 2 years following diagnosis of HIV-HD. Fifty-seven patients with HIV-HD diagnosed between 1990 and 2002 were included in the study," said C. Hoffmann and coworkers.
"In the Cox model," Hoffmann continued, "the only factors independently associated with OS were HAART response [relative hazard (RH) 0.19; 95% confidence interval (CI) 0.06-0.60], complete remission (RH 0.30, 95% CI 0.13-0.72) and age less than or equal to5 years (RH 0.23; 95% Cl 0.09-0.60).
"Median survival time in patients without HAART response was 18.6 months, whereas the median survival time in patients with HAART response was not reached (89% OS at 24 months)."
"In this cohort, a significant improvement in survival was found in patients with HIV-HD who responded to HAART," the authors concluded.
Hoffmann and colleagues published their study in British Journal of Haematology (Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin disease. Br J Haematol. 2004 May;125(4):455-62).
For more information, contact C. Hoffmann, University Klinikum Schleswig Holstein, HIV Ambulanz Kiel, CAmpus Kiel, Chemnitzstr 33, D-24116 Kiel, Germany.
Publisher contact information for the British Journal of Haematology is: Blackwell Publishing Ltd., 9600 Garsington Rd., Oxford OX4 2DG, Oxon, England.
The information in this article comes under the major subject areas of AIDS/HIV, Immunology, Prognosis, Oncology and Antiretroviral Therapy.
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
Hoffmann C, Chow KU, Wolf E, et al., "Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease", Br J Haematol. 2004 May;125(4):455-62.
PubMED Related articles Search
040802
AW040803
Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.